Sign Out
Sitagliptin phosphate + Metformin hydrochloride (TIGLIPZA PLUS) is contraindicated in patients with: Severe renal impairment, (eGFR <30 mL/min/1.73 m2) (see Monitoring of renal function under Precautions).
Known hypersensitivity to sitagliptin phosphate, metformin hydrochloride known hypersensitivity to sitagliptin phosphate, metformin hydrochloride or any other component of Sitagliptin phosphate + Metformin hydrochloride (TIGLIPZA PLUS) (see Sitagliptin phosphate: Hypersensitivity Reactions under Precautions and Post-marketing Experience under Adverse Reactions).
Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
Sitagliptin phosphate + Metformin hydrochloride (TIGLIPZA PLUS) should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function (see Metformin Hydrochloride under Precautions).
Continue with Google